Literature DB >> 18946747

Current research topics in endocrine therapy for breast cancer.

Hiroko Yamashita1.   

Abstract

There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers. Endocrine therapy has become the most important treatment option for women with ER-positive breast cancer, and approximately 70% of primary breast cancers express ERalpha. Endocrine therapy has provided meaningful advances in breast cancer treatment and prevention. However, some patients continue to develop recurrence and die of the disease. New insights into ER biology and progress in the understanding of resistance mechanisms are generating tremendous promise for new therapeutic opportunities to target resistance and improve disease outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946747     DOI: 10.1007/s10147-008-0818-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  39 in total

1.  Activation of PI3K/Akt signaling and hormone resistance in breast cancer.

Authors:  Eriko Tokunaga; Yasue Kimura; Kojiro Mashino; Eiji Oki; Akemi Kataoka; Shinji Ohno; Masaru Morita; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Breast Cancer       Date:  2006       Impact factor: 4.239

2.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

Authors:  M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

Review 3.  Estrogen receptor mutations in human disease.

Authors:  Matthew H Herynk; Suzanne A W Fuqua
Journal:  Endocr Rev       Date:  2004-12       Impact factor: 19.871

Review 4.  Epigenetic information and estrogen receptor alpha expression in breast cancer.

Authors:  Laura Giacinti; Pier Paolo Claudio; Massimo Lopez; Antonio Giordano
Journal:  Oncologist       Date:  2006-01

5.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

6.  Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Authors:  Rinaa S Punglia; Harold J Burstein; Eric P Winer; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

7.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Authors:  Naoto Kondo; Tatsuya Toyama; Hiroshi Sugiura; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

8.  Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

Authors:  Y Xu; Y Sun; L Yao; L Shi; Y Wu; T Ouyang; J Li; T Wang; Z Fan; T Fan; B Lin; L He; P Li; Y Xie
Journal:  Ann Oncol       Date:  2008-04-11       Impact factor: 32.976

9.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

10.  A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

Authors:  Laurel A Habel; Steven Shak; Marlena K Jacobs; Angela Capra; Claire Alexander; Mylan Pho; Joffre Baker; Michael Walker; Drew Watson; James Hackett; Noelle T Blick; Deborah Greenberg; Louis Fehrenbacher; Bryan Langholz; Charles P Quesenberry
Journal:  Breast Cancer Res       Date:  2006-05-31       Impact factor: 6.466

View more
  18 in total

1.  Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.

Authors:  Xin Pan; Tao Zhou; Yan-Hong Tai; Chenguang Wang; Jie Zhao; Yuan Cao; Yuan Chen; Pei-Jing Zhang; Ming Yu; Cheng Zhen; Rui Mu; Zhao-Fang Bai; Hui-Yan Li; Ai-Ling Li; Bing Liang; Zhao Jian; Wei-Na Zhang; Jiang-Hong Man; Yan-Fei Gao; Wei-Li Gong; Li-Xin Wei; Xue-Min Zhang
Journal:  Nat Med       Date:  2011-05-15       Impact factor: 53.440

2.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

3.  Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.

Authors:  Han Li; Guo-feng Pan; Zhen-zhou Jiang; Jing Yang; Li-xin Sun; Lu-yong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-04-13       Impact factor: 6.150

Review 4.  CUEDC2: an emerging key player in inflammation and tumorigenesis.

Authors:  Jianghong Man; Xuemin Zhang
Journal:  Protein Cell       Date:  2011-10-06       Impact factor: 14.870

5.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

6.  Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

Authors:  Jie Chen; Ana R Gomes; Lara J Monteiro; San Yu Wong; Lai Han Wu; Ting-Ting Ng; Christina T Karadedou; Julie Millour; Ying-Chi Ip; Yuen Nei Cheung; Andrew Sunters; Kelvin Y K Chan; Eric W-F Lam; Ui-Soon Khoo
Journal:  PLoS One       Date:  2010-08-20       Impact factor: 3.240

7.  Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

Authors:  Xinyan Wu; Muhammad Saddiq Zahari; Santosh Renuse; Raja Sekhar Nirujogi; Min-Sik Kim; Srikanth S Manda; Vered Stearns; Edward Gabrielson; Saraswati Sukumar; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2015-09-01       Impact factor: 5.911

8.  ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.

Authors:  Julie Millour; Natalia de Olano; Yoshiya Horimoto; Lara J Monteiro; Julia K Langer; Rosa Aligue; Nabil Hajji; Eric W F Lam
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

9.  GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer.

Authors:  Mingli Liu; Guangdi Wang; Carmen R Gomez-Fernandez; Shanchun Guo
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

10.  Activation of rapid oestrogen signalling in aggressive human breast cancers.

Authors:  Coralie Poulard; Isabelle Treilleux; Emilie Lavergne; Katia Bouchekioua-Bouzaghou; Sophie Goddard-Léon; Sylvie Chabaud; Olivier Trédan; Laura Corbo; Muriel Le Romancer
Journal:  EMBO Mol Med       Date:  2012-10-15       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.